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A series of oligoarginine peptide derivatives containing 
cyclometallated iridium(III) units display remarkable cytotoxicity, 
comparable to that of cisplatin. In vitro studies with unilamellar 
vesicles support a membrane-disrupting mechanism of action 
Cancer is one of the leading causes of death and morbidity 
worldwide.
1
 Recent high-throughput sequencing studies have 
shown that thousands of different mutations can lead to 
cancer development, and that the mutational signature of 
cancer is highly dynamic and heterogeneous, even between 
parts of individual primary tumors.
2
 These results suggest that 
anticancer strategies that target a single oncogene will likely 
fail to deliver effective treatments, and support the use of 
combination therapies.
3
 Unfortunately, the convergence of 
most of the standard chemotherapeutic agents on a small 
number of pathways—particularly DNA synthesis and 
transcription—have hampered the development of successful, 
and much needed, combined treatments.
4
 In this context, 
membrane-disrupting lytic peptides have surfaced as potential 
chemotherapeutic agents.
5
 In contrast with current anticancer 
drugs, the mode of action of these anticancer peptides (ACPs) 
is not linked to any particular molecular target, but to the 
selective and fast damage of malignant cell membranes, which 
typically present altered composition,
6
 thus avoiding the 




 ACPs are structurally diverse, but often contain cationic 
sequences with arginine residues and hydrophobic clusters.
8
 
While the role of the guanidine groups of the Arg side chains in 
the interaction and disruption of the lipid bilayer has been 
extensively studied,
9
 the mechanistic influence of the 
hydrophobic residues is still less clear.
10
 However, although 
not fully understood, it appears that tryptophan side chains, 
which combine an extended π-electron system with a high 
quadrupole moment, are crucial for the lipid bilayer disruption 
effect,
 11
 and that replacement of Trp by Gly, or even by other 
aromatic residue such as Phe, results in many cases in 
complete loss of activity.
12
 Interestingly, cyclometalated 
iridium(III) complexes display extended aromatic surfaces and 
relatively low cationic charge, and therefore could potentially 
act as functional substitutes of Trp residues in ACPs. Moreover, 
cyclometalated Ir(III) complexes display intrinsic cytotoxicity 
and rich photophysical properties, e.g., high quantum yields, 
good photostability, and long-lived excited states, that can be 
easily modulated by appropriate selection of the ancillary 
ligands, thus providing a privileged platform for the 
exploration of novel ACPs with theranostic potential.
13
 
Considering the beneficial effects of conformational restriction 
and backbone rigidity in the properties of lytic pepides,
14
 we 
also decided to explore the effect of cyclization in the activity 
of the iridium organometallopeptides. Therefore, we report 
herein the application of standard solid-phase peptide 
synthesis (SPPS) methods for the straightforward preparation 
of a set of cationic linear and cyclic oligopeptides featuring 
two, or three cyclometalated Ir(III) 2-phenylpyridine (ppy) 
complexes: Ir2-R8,
15
 (Ir-R3)2, (Ir-R3)3, cyclo-(Ir-R3)2, and  
cyclo-(Ir-R3)3 (Fig. 1), as well as the evaluation of their 
cytotoxicity and membrane transport properties. 
 The SPPS approach relies on the preparation of an 
appropriately derivatized 2,2’-bipyridine (bpy) ligand in the 
form of an Fmoc-protected amino acid.
16
 Thus, the synthesis of 
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the bpy amino acid building block was achieved according to 
previously reported procedures developed in house.
17
 For 
solubility and reactivity reasons, the 2’-amino group in the bpy 
was modified with Fmoc-β-Alanine (Fmoc–βAla-bpy–OH 1).  
 
Fig 1. Top: Synthesis of the iridium(III) cyclo-(Ir-R3)2 peptide. Bottom: sequences 
of the peptides used in this study. Structure of the βAla-bpy[Ir(ppy)2]
+ unit. CTC 
resin = Chlorotrityl chloride resin. 
Having at hand the desired bpy building block, we carried out 
the synthesis of the cyclometalated iridium(III) peptides 
following standard Fmoc/tBu solid-phase protocols,
18
 as 
exemplified with the synthesis of the cyclo-(Ir-R3)2 peptide 
(Fig. 1). Brifely, after the assembly of the peptidic chain and its 
cleavage/deprotection using the standard acidic cocktail (ESI†), 
the peptide chain was purified by HPLC and subjected to the 
macrocyclization conditions by treatment with PyAOP/DIEA in 
DMF. The resulting cyclopeptide was reacted in CH3CH/H2O 
with the ortho-metalated dimer precursor [Ir(ppy)2Cl]2, 
obtained by a modification of the procedure reported by 
Sprouse.
19
 The reaction proceeds in mild conditions, and the 
final peptide was obtained in good yields after HPLC 
purification. Similar procedures were followed for the 
synthesis of the rest of the iridium(III) metallopeptides (ESI†). 
Additionally, the tryptophan analog cyclo-(W-R3)2 was also 
synthesized as control. 
 Once we synthesized the set of iridium(III) metallopeptides, 
we studied their cytotoxicity in two tumoral cell lines, NCI-
H460, a lung cancer cell line,
20
 and NCI/ADR-RES, which has 
been widely used as a multidrug-resistant breast cancer cell 
model in cancer research,
21
 as well as in non-transformed lung 
fibroblasts (MRC-5).
22
 The dose-response curves were analyzed 
and the results, summarized in Table 1, show that the IC50 
values of all the cyclometalated iridium peptides are in the 
same range to that of cisplatin.
23
 Thus, for example, the linear 
peptides Ir2-R8 and (Ir-R3)2 have an IC50 values of 15 and 13 µM 
for NCI/ADR-RES, respectively, matching the IC50 obtained for 
cisplatin within the error of the experiment. Likewise, the 
cyclic peptides cyclo-(Ir-R3)2 and cyclo-(Ir-R3)3 display IC50 
values in a similar same range (19 and 21 µM in NCI/ADR-RES 
cell lines). The peptides display roughly the same toxicity 
against the NCI-H460 cells, and a slight reduction in IC50 values 
against normal fibroblasts. Interestingly, while the potency of 
these iridium metallopeptides evidenced by the IC50 values is 
fairly similar to that of cisplatin, their Emax was in all cases 
significantly higher than those of cisplatin. For instance, the 
measured Emax values for cisplatin were ≈ 83 µM and ≈ 68 µM 
for the two cancer lines, whereas all the iridium(III) peptides 
showed Emax values over 90, showing higher potency than 
cisplatin for the tumor lines under the same experimental 
conditions.
24
 Curiously, in contrast with similar Arg/Trp rich 
peptides,
25
 these metallopeptides did not display significant 
antibacterial properties (data not shown). 
Table 1. MTT cytotoxicity assays of the cyclometalated peptides. IC50 values are 
reported in µM, and Emax in %. 
 NCI/ADR-RES NCl-H460 MRC-5 
 IC50 Emax IC50 Emax IC50 Emax 
cisplatin 14(1) 83(1) ∼6(0.1) 68(2) ∼7(0.3) 91(1) 
Ir2-R8 15(1) 92(1) 15(0.1) 91(1) 22(2) 89(1) 
(Ir-R3)2 13(1) 91(1) 21(1) 91(1) 26(2) 91(1) 
(Ir-R3)3 45(1) 91(1) 34(1) 93(2) ∼4(0.1) 84(1) 
cyclo-(Ir-R3)2 19(1) 92(1) 36(1) 91(1) 16(1) 90(1) 
cyclo-(Ir-R3)3 21(1) 91(1) 17(1) 92(1) 17(2) 91(1) 
cyclo-(W-R3)2 41(1) 87(1) 47(1) 94(1) 50(3) 95(2) 
 
Intrigued by the high cytotoxicity of these metallopeptides we 
decided to study them by fluorescence microscopy. Thus, Vero 
cells in DMEM medium were incubated for 30 min with 
peptides (Ir-R3)2, cyclo-(Ir-R3)2, and cyclo-(Ir-R3)3 at 37 °C, and 
observed in the fluorescence microscope. The resulting 
micrographs show that the compounds have a strong lytic 
effect, and that the cell membranes are rapidly disrupted in 
the presence of the metallopeptides, which aggregate 
exclusively in the surface of the cells forming highly 
luminescent membrane protrusions (Fig. 2).  
  
Fig 2. a) Representative fluorescence images of the iridium metallopeptides, in 
this case with Vero cells incubated with 20 µM cyclo-(Ir-R3)2 for 30 min. Similar 
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experiments have been performed with all the cyclopeptides with equivalent 
results. a) Aggregation of the cyclometallopeptide in the cells and not in the 
culture medium or the plate surface; b) detail of the cells showing that the 
peptide is concentrated at particular spots in the surface of the cells (white 
arrows); c) confocal XZ-section of Fluorescein-conjugated concanavalin A-stained 
cell membrane (green),
26
 costained with cyclo-(Ir-R3)2 (red) showing the peptide 
colocalizing with the membrane marker.  
Membrane integrity was further studied with the trypan blue 
exclusion assay, in which cells with damaged membranes are 
stained in a characteristic blue color readily observed under 
the microscope.
27
 Vero cells were incubated for 1 h  with 20 
µM cyclo-(Ir-R3)2, washed, stained with trypan blue, and 
monitored for 1 h. Gratifyingly, the cells in the preparation 
quickly internalized the trypan blue, and were progressively 
stained so that all of them were blue after 1 h, thus 
demonstrating that the cyclometallopeptides lead to plasma 
membrane permeabilization (ESI†). The morphology of these 
peptide aggregates on the membranes suggests a detergent-
type membrane lytic mechanism in which the peptides localize 
and aggregate on the cell membrane, until they reach a 
threshold local concentration that allows them to behave like 
detergents and thus degrade the phospholipid bilayer causing 
cell death.
28
 These observations support a plausible 
mechanism of action based on the fast physical degradation of 
the lipid bilayer, which occurs at a much faster timescale than 
the toxicity effects of cisplatin. 
 To get further insights into the potential membrane 
disruption mechanism of the Ir(III) metallopeptides, we 
decided to perform model experiments in fluorogenic artificial 
vesicles. Therefore, we prepared zwiterionic large unilamellar 
vesicles from egg yolk phosphatidylcholine (EYPC LUVs) with 
entrapped carboxyfluorescein (CF) at self-quenched 
concentration (see the ESI†). Addition of membrane lytic 
compounds to isosmotic buffered suspensions of these 
liposomes triggers the escape, dilution and subsequent 
enhance of the fluorescence emission of the released CF.
29
 CF 
leakage experiments confirmed the very strong lytic activities 
for all metallopeptides reported in this study (Fig. 3). The 
values of the maximal activity (YMax) and the concentration 
required to achieve half of the maximal activity (EC50) matched 
fairly well with the observed cellular activity so that, as 
observed in cytotoxicity assays, the linear peptides showed a 
slightly higher membrane leakage than their cyclic 
counterparts (Fig. 3, Table 1).  
 Remarkably, the nanomolar activity observed for the 
assayed metallopeptides is three orders of magnitude higher 
than membrane disruption strength of the potent detergent 
Triton-X (EC50 = 100 µM, ESI†). This outstanding membrane 
disrupting activity might be related with an in-plane disruption 
mechanism in which very small amounts of metallopeptides 
induce wave-like membrane perturbations that feedback and 
reinforce each other leading to strong membrane curvature 
and membrane collapse.
30
 Interestingly, all the Ir(III) 
metallopeptides display higher maximal activity (YMax) and 
lower EC50 than the tryptophan control cyclo-(W-R3)2, which 
lacks the metal centres. This result highlights the beneficial 
role of the cyclometalated Ir(III) complex in the membrane 
disruption mechanism and it is consistent with the higher 
cytotoxicity of the iridium metallopeptides. 
 In summary, we have synthesized a new family of 
cyclometalated Ir(III) oligocationic peptides that display potent 
lytic properties, and antitumoral activity comparable to that of 
cisplatin. The luminescent properties of these peptides 
allowed us to observe their aggregation on the cell 
membranes, highlighting the analytical potential of these 
metallopeptides. Furthermore, the peptidic nature of these 
cytotoxic probes opens the door the straightforward 
modulation of their cytotoxicity through judicious modification 
of the peptide sequence, or repositioning of the metal centers, 




Fig 3. Top: cartoon showing the basics of the membrane disruption experiment 
in which CF increases its emission upon LUV disruption. Bottom: Dose-response 
curves of carboxyfluorescein efflux from EYPC LUVs. Each curve was obtained by 
fitting the data to the Hill equation (see ESI†). (Ir-R3)3 (), (Ir-R3)2 (▲),  
cyclo-(Ir-R3)3 (○), cyclo-(Ir-R3)2 (●), and cyclo-(W-R3)2 (◆). 
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